96 studies found for:    PALO-10-20
Show Display Options
Rank Status Study
1 Completed
Has Results
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Palonosetron;   Drug: Ondansetron;   Drug: Placebo to Ondansetron;   Drug: Placebo to Palonosetron
2 Completed
Has Results
Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
Condition: Postoperative Nausea and Vomiting
Interventions: Drug: Palonosetron;   Drug: Ondansetron;   Drug: Placebo to Ondansetron;   Drug: Placebo to Palonosetron
3 Recruiting Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Condition: Recurrent Neuroblastoma
Interventions: Drug: temozolomide;   Drug: irinotecan hydrochloride;   Drug: temsirolimus;   Biological: dinutuximab;   Biological: sargramostim;   Other: laboratory biomarker analysis
4 Active, not recruiting Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel poliglumex;   Other: clinical observation;   Drug: paclitaxel
5 Recruiting Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: isotretinoin;   Biological: sargramostim;   Biological: dinutuximab;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Other: pharmacological study
6 Terminated
Has Results
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: Apremilast 30 mg;   Drug: Apremilast 20 mg;   Drug: Placebo
7 Completed
Has Results
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Interventions: Drug: Adalimumab;   Drug: CP-690-550;   Drug: CP-690,550;   Drug: Placebo
8 Not yet recruiting Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers
Condition: Huntington's Disease
Interventions: Drug: PBF-999;   Drug: Placebo
9 Completed
Has Results
A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)
Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 4 mg/kg;   Drug: Belimumab 10 mg/kg
10 Recruiting Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment
Condition: Chronic Hepatitis B
Interventions: Drug: TDF;   Biological: GS-4774
11 Completed
Has Results
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550;   Drug: Placebo
12 Recruiting Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-680 After Multiple Oral Doses" in Healthy Volunteers.
Condition: Asthma
Interventions: Drug: PBF-680;   Drug: Placebo
13 Active, not recruiting Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Indolent Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma
Interventions: Drug: Idelalisib;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Ofatumumab;   Drug: Fludarabine;   Drug: Everolimus;   Drug: Bortezomib;   Drug: Chlorambucil;   Drug: Lenalidomide
14 Terminated
Has Results
Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Abatacept;   Drug: Placebo
15 Recruiting Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex
Condition: Bipolar I Disorder
Interventions: Drug: Lurasidone;   Drug: Placebo
16 Completed
Has Results
Methotrexate-Inadequate Response Study
Condition: Rheumatoid Arthritis (RA)
Interventions: Drug: Subcutaneous (SC) Abatacept;   Drug: Intravenous (IV) Abatacept
17 Completed
Has Results
Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium;   Drug: Placebo
18 Active, not recruiting Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Condition: Major Depressive Disorder With Mixed Features
Interventions: Drug: Lurasidone;   Drug: Placebo
19 Completed Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate
20 Completed
Has Results
Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept;   Drug: Placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years